恶唑-5-甲醛 | 118994-86-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 恶唑-5-甲醛
• 中文别名: 5-恶唑甲醛；5-噁唑羧醛
• 英文名称: oxazole-5-carbaldehyde
• 英文别名: oxazole-5-carboxaldehyde；5-Oxazolecarboxaldehyde；1,3-oxazole-5-carbaldehyde
• CAS: 118994-86-8
• 化学式: C₄H₃NO₂
• mdl: MFCD02179513
• 分子量: 97.0733
• InChiKey: YOFJBRZKRZUDGB-UHFFFAOYSA-N

物化性质

• 熔点：
  30-32℃
• 沸点：
  184.7±13.0 °C(Predicted)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317,H319
• 储存条件：
  -20°C，采用惰性气体保存

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Oxazole-5-carboxaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H317: May cause an allergic skin reaction
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Oxazole-5-carboxaldehyde
CAS number: 118994-86-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H3NO2
Molecular weight: 97.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备

化合物恶唑通过Vilsmeier-Hacck反应与三氯氧磷和N,N-二甲基甲酰胺合成了化合物恶唑-5-甲醛。该工艺路线操作简便，收率高，适于工业化生产。

实验操作：

方法一：

在100mL三颈瓶中加入7.0mL N,N-二甲基甲酰胺，并将其冷却至0～5℃。缓慢滴加1.0mL三氯氧磷，继续搅拌20min后，在10℃以下条件下滴加1.9g（10mmol）恶唑溶于3.0mL N,N-二甲基甲酰胺的溶液。滴毕，将反应温度升至35℃并反应1h。

冰水冷却下加入10mL水，并用15%氢氧化钠调节pH值至中性，然后回流20min后冷却，即可得到类白色固体。通过硅胶柱层析纯化可得到目标化合物恶唑-5-甲醛。

方法二：

在50mL烧瓶中加入5mL N,N-二甲基甲酰胺，并将其冷却至0～5℃。缓慢滴加0.5mL三氯氧磷，继续搅拌20min后，在10℃以下条件下将恶唑溶解于2mL N,N-二甲基甲酰胺中并滴加到反应瓶中。升温至35℃并反应1h。

在冰水冷却下向反应液中加入3mL水，并用30%氢氧化钠水溶液调节pH值至8～9，然后回流1h后放置室温。将反应液缓慢倒入水中搅至固体最多，抽滤得粗产物，再用甲醇重结晶可得到恶唑-5-甲醛。

反应信息

• 作为反应物：
  描述：

  恶唑-5-甲醛 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 噁唑-5-甲醇
  参考文献：
  名称：

  Enantioselective total synthesis of neooxazolomycin

  摘要：

  DOI：

  10.1021/ja00166a072
• 作为产物：
  描述：

  噁唑-5-甲醇 在 2-碘酰基苯甲酸 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 恶唑-5-甲醛
  参考文献：
  名称：

  Vinylnaphthalene-bearing hexaoxazole as a fluorescence turn-on type G-quadruplex ligand

  摘要：

  开发了含有乙烯基萘基团的环状六氧杂唑，作为一种荧光开启配体，选择性地针对G四链体。

  DOI：

  10.1039/d1ob01500a

文献信息

• [EN] Pan-Tropic Entry Inhibitors<br/>[FR] INHIBITEURS D'ENTRÉE PANTROPIQUE
  申请人：UNIV EMORY

  公开号：WO2019183133A1

  公开（公告）日：2019-09-26

  This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

  本公开涉及按照式(I)的化合物、盐、前药和含有该化合物的药物配方，用于治疗与CXCR4和CCR5相关的疾病。这些疾病可能包括病毒感染、异常细胞增殖、视网膜退化和炎症性疾病，或者这些化合物可以用作免疫刺激剂或免疫抑制剂。此外，这些化合物可以与另一种来自抗病毒药物或化疗药物的活性成分结合使用。
• Charge Transport and Quantum Interference Effects in Oxazole-Terminated Conjugated Oligomers
  作者：Songsong Li、Hao Yu、Kenneth Schwieter、Kejia Chen、Bo Li、Yun Liu、Jeffrey S. Moore、Charles M. Schroeder

  DOI：10.1021/jacs.9b08427

  日期：2019.10.9

  anchor group to form stable gold-molecule-gold junctions. We further observe quantum interference (QI) effects in oxazole-terminated phenylene molecular junctions, including destructive QI in meta-substituted phenyl rings and constructive QI in para-substituted phenyl rings containing terminal oxazole groups with the same chemical constitution on both termini (i.e. O5O5 (5-oxazolyl) or O4O4 (4-oxazolyl)

  单分子结中的电荷传输主要取决于用于将分子线连接到电极的锚定基团的化学特性。在这项工作中，我们报告了带有恶唑锚的共轭低聚物的电荷传输特性，重点是杂原子取代位置在末端恶唑基团中的作用。我们的结果表明，恶唑可作为形成稳定的金-分子-金连接的有效锚定基团。我们进一步观察了恶唑封端的亚苯基分子结中的量子干涉 (QI) 效应，包括间位取代苯环中的破坏性 QI 和对位取代苯环中含有两个末端具有相同化学组成的对位取代苯环的建设性 QI（即 O5O5 （5-恶唑基）或 O4O4（4-恶唑基）连接在两个末端）。出奇，与对位取代的类似物相比，具有非等价结构（即 O4O5 恶唑末端连接）的间位取代苯环显示出意外更高的电导率。这些结果表明，除了 pi 共轭核的芳基取代模式之外，恶唑末端分子中的电荷传输还由恶唑锚的杂原子取代位置决定。我们的结果进一步表明，具有均质恶唑键的共轭分子遵循量子电路规则，即 G_O4-p-O4/G_O4-m-O4
• Retroviral protease inhibiting piperazine compounds
  申请人：Abbott Laboratories

  公开号：US05455351A1

  公开（公告）日：1995-10-03

  Retroviral protease inhibiting compounds of the formula: ##STR1## are disclosed.

  翻译结果为：公开了具有以下公式的逆转录病毒蛋白酶抑制化合物：##STR1##。
• N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors
  作者：Alessia Petrocchi、Philip Jones、Michael Rowley、Fabrizio Fiore、Vincenzo Summa

  DOI：10.1016/j.bmcl.2009.05.098

  日期：2009.8

  A novel class of tetrahydro-pyrazinopyrimidine-2-carboxamides have been identified as HIV-1 integrase inhibitors. Optimization of the initial lead culminated in the discovery of a series of compounds with high potency on the enzyme and an antiviral cell-based activity equivalent to that showed by Raltegravir, the first in class HIV-1 integrase inhibitor.

  一类新型的四氢吡喃并嘧啶-2-羧酰胺已被鉴定为HIV-1整合酶抑制剂。初始铅的优化最终发现了一系列对酶具有高效力的化合物，其抗病毒细胞活性与Raltegravir（第一种HIV-1整合酶抑制剂）所显示的活性相当。
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。